PHATHOM PHARMACEUTICALS, INC. Capital Expenditures
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Capital Expenditures of $105.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $44.00K, a 54.64% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $61.00K, a 238.89% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $87.00K, a 1640.00% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $27.00K, a 38.64% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $229.00K, a 69.63% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $135.00K, a 91.74% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $1.63M, a 56.96% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $1.04M, a 217.38% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $105.00K 10-Q · filed 2026-07-30 | $192.00K derived: sum of 3 quarters · filed 2026-07-30 | $219.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $61.00K 10-Q · filed 2026-04-30 | $148.00K derived: sum of 2 quarters · filed 2026-04-30 | $175.00K derived: sum of 3 quarters · filed 2026-04-30 | $272.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $114.00K derived: sum of 2 quarters · filed 2026-02-26 | $211.00K derived: sum of 3 quarters · filed 2026-07-30 | $229.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $124.00K derived: sum of 2 quarters · filed 2026-07-30 | $142.00K 10-Q · filed 2025-10-30 | $147.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $115.00K 10-Q · filed 2026-07-30 | $120.00K derived: sum of 3 quarters · filed 2026-07-30 | $164.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $18.00K 10-Q · filed 2026-04-30 | $23.00K derived: sum of 2 quarters · filed 2026-04-30 | $67.00K derived: sum of 3 quarters · filed 2026-04-30 | $113.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.00K derived: sum of 2 quarters · filed 2026-02-26 | $95.00K derived: sum of 3 quarters · filed 2026-02-26 | $135.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $90.00K derived: sum of 2 quarters · filed 2025-10-30 | $130.00K 10-Q · filed 2025-10-30 | $605.00K derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $86.00K 10-Q · filed 2025-08-07 | $561.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $40.00K 10-Q · filed 2025-05-01 | $515.00K derived: sum of 2 quarters · filed 2025-05-01 | $1.45M derived: sum of 3 quarters · filed 2025-05-01 | $1.46M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $475.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.41M derived: sum of 2 quarters · filed 2025-03-06 | $1.42M derived: sum of 3 quarters · filed 2025-03-06 | $1.63M 10-K · filed 2025-03-06 |
| 2023-09-30 | $939.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $945.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.16M 10-Q · filed 2024-11-07 | $1.57M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $6.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $220.00K 10-Q · filed 2024-08-08 | $632.00K derived: sum of 3 quarters · filed 2024-08-08 | $766.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $214.00K 10-Q/A · filed 2024-06-14 | $626.00K derived: sum of 2 quarters · filed 2024-06-14 | $760.00K derived: sum of 3 quarters · filed 2024-06-14 | $1.19M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $412.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $546.00K derived: sum of 2 quarters · filed 2024-06-14 | $974.00K derived: sum of 3 quarters · filed 2024-06-14 | $1.04M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $562.00K derived: sum of 2 quarters · filed 2023-11-09 | $629.00K 10-Q · filed 2023-11-09 | $729.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $428.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $495.00K 10-Q · filed 2023-08-10 | $595.00K derived: sum of 3 quarters · filed 2023-08-10 | $609.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $67.00K 10-Q · filed 2023-05-10 | $167.00K derived: sum of 2 quarters · filed 2023-05-10 | $181.00K derived: sum of 3 quarters · filed 2023-05-10 | $226.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $114.00K derived: sum of 2 quarters · filed 2023-02-28 | $159.00K derived: sum of 3 quarters · filed 2023-02-28 | $328.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $14.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | $59.00K derived: sum of 2 quarters · filed 2022-11-09 | $228.00K 10-Q/A · filed 2022-11-09 | $352.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $214.00K 10-Q · filed 2022-08-02 | $338.00K derived: sum of 3 quarters · filed 2022-08-02 | $521.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $169.00K 10-Q · filed 2022-05-10 | $293.00K derived: sum of 2 quarters · filed 2022-05-10 | $476.00K derived: sum of 3 quarters · filed 2022-05-10 | $533.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $307.00K derived: sum of 2 quarters · filed 2022-03-01 | $364.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.04M 10-K · filed 2022-03-01 |
| 2020-09-30 | $183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $240.00K derived: sum of 2 quarters · filed 2021-11-08 | $916.00K 10-Q · filed 2021-11-08 | $1.02M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $733.00K 10-Q · filed 2021-08-10 | $839.00K derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $676.00K 10-Q · filed 2021-05-11 | $782.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $132.00K 10-K · filed 2021-03-30 | ||
| 2019-09-30 | $26.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |